share_log

Achieva Medical Entered Into an Exclusive Distribution Agreement With NowYon Medical

Achieva Medical Entered Into an Exclusive Distribution Agreement With NowYon Medical

Achieva Medical已与NowYon Medical签订了独家分销协议
PR Newswire ·  08/28 04:40

SUZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced that its wholly-owned subsidiary, Achieva Medical Limited ("Achieva Medical"), entered into an exclusive distribution agreement with Jiangsu NowYon Medical Limited ("NowYon Medical"). The agreement marks a significant milestone in the expansion of Peijia Medical's Neurointerventional Business in the Greater China region.

中国苏州,2024年8月28日 /美通社/ -- 中国领先的国内主要市场参与者佩佳医疗 (HKG:9996),宣布旗下全资子公司艾维美尔有限公司 ("艾维美尔") 与江苏诺永医疗有限公司 ("诺永医疗") 签署了独家分销协议。该协议标志着佩佳医疗在大中华区域神经介入业务扩张的重要里程碑。

Under the terms of the agreement, Achieva Medical has been appointed as the exclusive distributor for NowYon Medical's innovative YonFlow flow diverter, the first retrievable stent system after complete release globally. In January 2023, the product passed the innovative medical device review and was accepted by the Special Review and Approval Procedure for Innovative Medical Devices of the National Medical Products Administration (NMPA). In addition, the application for the registration approval of YonFlow has been submitted to the NMPA, which is expected to be approved soon.

根据协议的条款,艾维美尔被任命为诺永医疗创新的YonFlow分流器的独家分销商,该产品是全球首个可回收植入式支架系统。2023年1月,该产品通过了创新医疗器械审查,并获得国家药品监督管理局创新医疗器械专项审批程序的接受。此外,YonFlow的注册批准申请已提交给国家药品监督管理局,预计将很快获得批准。

"This strategic collaboration with NowYon Medical is a testament to our commitment to bringing cutting-edge medical solutions to patients in need and will continue to consolidate our leading position in the neurovascular interventions market in China." said Dr. Yi Zhang, Chairman and CEO of Peijia Medical. "We are excited about the potential of the YonFlow flow diverter and its impact on improving patient outcomes."

佩佳医疗董事长兼首席执行官张毅博士表示:“与诺永医疗的战略合作,证明了我们致力于将尖端医疗解决方案带给有需求的患者,并将继续巩固我们在中国神经介入市场的领先地位。尤其我们对YonFlow分流器的潜力以及它对改善患者预后的影响感到兴奋。”

About Peijia Medical
Peijia Medical (9996.HK) was established in 2012 and is headquartered in Suzhou, China. Peijia Medical focuses on the high-growth interventional procedural medical device market in China and aims to become a world-renowned medical device platform that provides comprehensive treatment solutions for structural heart and neurovascular diseases. The Company now has three TAVR systems and sixteen neurointerventional devices commercialized in China and various innovative product candidates at different stages of development.

关于佩佳医疗
佩佳医疗 (9996.HK) 成立于2012年,总部位于中国苏州。佩佳医疗专注于中国高增长介入性手术医疗器械市场,并力争成为全球著名的医疗器械平台,为结构性心脏病和神经血管疾病提供全面的治疗方案。公司目前在中国商业化的有三个TAVR系统和十六种神经介入装置,并有多个创新产品候选进展到不同的开发阶段。

For more information about Peijia, please visit peijiamedical.com/about.

想了解更多关于佩佳的信息,请访问peijiamedical.com/about。

About Achieva Medical
Achieva Medical, a wholly-owned subsidiary of Peijia Medical (9996.HK), is an innovative medical device company committed to development and manufacture of high-end neurointerventional medical devices. Achieva Medical now has sixteen commercialized products and various product candidates at different stage of development covering hemorrhagic stroke, ischemic stroke and vascular access.

关于成就医疗
成就医疗(9996.HK)是佩佳医疗的全资子公司,是一家致力于开发和制造高端神经介入医疗器械的创新型医疗器械公司。成就医疗目前已有十六种商品化产品,并有多种不同发展阶段的产品候选品,涵盖了出血性中风、缺血性中风和血管通路的解决方案。

About NowYon Medical
NowYon Medical is an innovative medical device company focusing on the development and manufacture of neurointerventional medical devices. Its product pipeline encompasses a range of solutions for hemorrhagic stroke, ischemic stroke and vascular access, including flow diverters, stent retrievers, aspiration catheters, balloon microcatheter, microcatheter, etc.

关于NowYon医疗
NowYon医疗是一家专注于开发和制造神经介入医疗器械的创新型医疗器械公司。其产品线包括一系列用于出血性中风、缺血性中风和血管通路的解决方案,包括转流器、取栓器、抽吸导管、气囊微导管、微导管等以太经典。

SOURCE Peijia Medical

培佳医疗

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发